Altered IL-6 and IP-10 levels in SLE patients and lupus relatives.

<p>Plasma levels of IL-6 (<b>A, C</b>) and IP-10 (<b>B, D</b>) were assessed in SLE patients (case), unaffected first-degree relatives of SLE patients (FDR), and unrelated, unaffected controls with no family history of SLE (Ctl). IL-6 (<b>C</b>) and IP-10 (<b>D</b>) levels are compared by genotype of associated SNPs rs76162067 and rs79711023, respectively. Data are presented as mean <u>+</u> SEM. *<i>p<0</i>.<i>05</i>, **<i>p<0</i>.<i>01</i>, ***<i>p<0</i>.<i>001</i>, ****<i>p<0</i>.<i>0001</i> by Kruskal-Wallis test with Dunn’s multiple comparison for all groups assessed (Case/FDR/Ctl [<b>A-B</b>]; Case/FDR/Ctl carrying major (CC) or minor (TC) alleles [<b>C-D</b>]). Only comparisons found to be statistically significant were marked.</p

European-American Study Participants.

<p>European-American Study Participants.</p

Genotypic Associations between <i>IFIH1</i> and Immune Mediators.

<p>Zoom plots of associations between SNPs in <i>IFIH1</i> and box-cox transformed plasma levels of (<b>A</b>) IL-6, (<b>B</b>) TNF-α, (<b>C</b>) IFN-β, (<b>D</b>) IP-10, (<b>E</b>) anti-dsDNA, and (<b>F</b>) total number of positive lupus-associated autoantibody specificities (dsDNA, chromatin, Ro/SSA, La/SSB, Sm, SmRNP, and nRNP, as described in <i>Materials and Methods</i>), displayed as negative log transformed p-values (y-axis). Red dots indicate SNPs within Exon 13. LD map of <i>IFIH1</i> SNPs is presented (<b>G</b>).</p

IFIH1 effect on plasma levels of IL-6 and IP-10.

<p>Exon map of IFIH1 is presented (<b>A</b>) containing labeled SNPs rs76162067 and rs79711023. IL-6 (<b>B</b>) and IP-10 (<b>C</b>) levels in study participants expressing the major (CC) or minor (CT) allele of SNP rs76162067 or rs79711023, respectively, are expressed as box-cox transformed (left y-axis) and concentration (right y-axis) values. Exon order is displayed L-R for ease of interpretation, although IFIH1 is transcribed R-L from the negative strand. Data in <b>B-C</b> are presented as median ± interquartile range. *<i>p≤0</i>.<i>05</i>, **<i>p<0</i>.<i>01</i> Mann-Whitney test.</p

Clinical features of the subjects in the study.

<p>Clinical features of the subjects in the study.</p

MiRNAs profile from monozygotic discordant twins.

<p>MiRNAs profile from monozygotic discordant twins.</p

MiRNAs differentially expressed in SLE European American samples derived cell lines.

<p>MiRNAs differentially expressed in SLE European American samples derived cell lines.</p

MiRNAs differentially expressed in SLE African American samples derived cell lines.

<p>MiRNAs differentially expressed in SLE African American samples derived cell lines.</p

The potential gene target for the primary differentially expressed miRNA.

<p>The potential gene target for the primary differentially expressed miRNA.</p

Frequencies of homozygous risk allele genotypes in Korean SLE patients compared to controls.

<p>OR, odds ratio; CI, confidence interval.</p>*<p>A total of 628 independent female SLE patients and 736 healthy unrelated female controls were genotyped</p